Ipilimumab waxaa ogolaatay Maamulka Cuntada iyo Maandooriyaha si loo daaweeyo melanoma. Tani waa war wanaagsan oo loogu talagalay bukaanada, kuwaas oo mudo dheer haysta fursado yar marka melanoma ay ku faafto meelaha kale ee jidhka ( marxalad IV ).
Waa maxay Melanoma?
Melanoma, nooca ugu caansan ee kansarka maqaarka, waxay ku dhacdaa unugyada (melanocytes) ee soo saaro melanin - midabka maqaarkaaga siinaya midabkiisa.
Melanomadu sidoo kale waxay ku sameysmi kartaa indhahaaga iyo, dhif ahaanta, xubnaha gudaha, sida xiidmahaaga.
Sidee Ipilumumab u shaqeysaa?
Ipilumumab waa unug udub dhexaad u ah habka difaaca jidhka si loola dagaalamo melanka iyadoo la xakameynayo cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) molecule. CTLA-4 waa molecule on T-yaryar, nooc ka mid ah unugyada dhiigga cad oo ka ciyaara kaalin muhiim ah oo lagu xakameynayo jawaabaha jirka ee dabiiciga ah. Joogista CTLA-4 waxay xakameysaa habka difaaca jirka ee cudurka, sidaa darteed xannibista hawshu waxay kicisaa nidaamka difaaca si loola dagaalamo melanoma.
Caddaynta in Ipilumumab uu shaqeynayo
Saddex waji ee kiliinikada II ee daaweynta ayaa muujisay in daaweynta ipilimumab ay ka dhalisay heerka hal sanno halista ah 47 ilaa 51 boqolkiiba dadka qaba marxaladda III ama IV melanoma, taas oo ku dhowaad laba laab celceliska.
Waxaa lagu tijaabiyaa tijaabooyin heer sare ah (waji III) iyada oo laysku darayo tallaalada, tallaalka kale (sida interleukin-2), iyo kiimiko (sida dacarbazine).
Heerarka jawaabta guud waxay ka dhigan tahay 13 boqolkiiba iyada oo la isticmaalayo ipilimumab oo lagu daray bukaanka qaba cudurka IV-da illaa 17 iyo 22 boqolkiiba oo leh ipilimumab iyo lamarbazine ama interleukin-2, siday u kala horreeyaan, bukaanka qaba cudurrada faafa. Jawaabaha waxay ahaayeen kuwo muddo dheer soconaya, iyo kuwa ka soo jeeda dhibaatooyin aad u daran, xitaa heerarka jawaabta sare ayaa la arkay (ilaa 36 boqolkiiba).
Natiijooyinkani waxay muujinayaan in in ka badan saddex-meelood hal bukaan oo qaba daawada ipilimumab-qabay ee leh melanada casriga ah ay la kulmaan faa'iidada mudada dheer ee noolaanshaha, oo ah sheeko naadir ah oo ku saabsan daaweynta cudurkan.
Saameynaha Sidee Ipilumumab
Si ka duwan kiimoterapia , taas oo saameynaha daawadu ay u muuqdaan isla markiiba ka dib marka la bilaabo daaweynta, saameynta daawada ee ipilimumab aad ayey u kala duwan tahay, sababtoo ah nidaamka difaaca jirka ayaa is bedelaya qof ahaan.
Dhibaatooyinka ugu badan ee ka yimaada ipilimumab waxay ku dhacaan marinka mindhicirka (sida shubanka iyo bararka caloosha) iyo maqaarka (sida finan yaryar iyo caabuq maqaarka). Waxyeellooyinka soo noqnoqda badanaa waxaa ka mid ah cagaarshow, caabuqa qanjirada pituitary (hypophysitis), bararka indhaha ( uveitis ), iyo dhibaatooyinka kelyaha (nephritis). Dhibaatooyinka kale waxay ku dhacaan ilaa 84 boqolkiiba bukaanada laakiin guud ahaan waa mid sahlan oo la daweyn karo.
> Ilo:
> Hersh E, Weber J, Powder J, iyo al (2009). Cudurrada muddada dheer ee bukaanada (pts) leh melanoma heer sare ah ayaa lagu daaweeyaa ipilimumab leh ama aan lahayn hoarbazine. J Clin Oncol 27: 15s (supplin; abstr 9038).
> Ledezma B (2009). Ipilimumab for melanoma hormarsan: Aragtida xanaanada. Oncol Nurs Forum, 36 (1), 97-104.
> Mayo Clinic. Kansarka Maqalka.
> Machadka Kansarka Qaranka. Ipilimumab
> Sarnaik AA, Weber JS (2009). Horumarka dhowaan la isticmaalayo anti-CTLA-4 ee daaweynta melanoma. Cancer J. 2009 May-Jun; 15 (3): 169-73.